Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v20-FR Version v1-EN
Language French English
Date Updated 2024-10-16 2023-08-17
Drug Identification Number 02313723 02313723
Brand name TARO-ATORVASTATIN TARO-ATORVASTATIN
Common or Proper name ATORVASTATIN ATORVASTATIN
Company Name TARO PHARMACEUTICALS INC TARO PHARMACEUTICALS INC
Ingredients ATORVASTATIN ATORVASTATIN
Strength(s) 40MG 40MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 500 500
ATC code C10AA C10AA
ATC description LIPID MODIFYING AGENTS, PLAIN LIPID MODIFYING AGENTS, PLAIN
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-08-10 2023-08-10
Estimated end date 2024-11-08 2023-08-31
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments